3.2 Regeneron / Hansoh (HS-20094 GLP-1/GIP Agonist) Deal: Regeneron (U.S.) in June 2025 licensed global rights (ex-China) to HS-20094 , a dual GLP-1/GIP agonist from Chinas Hansoh Pharma
Evidence-based formulations Pharmaceutical-grade ingredients Sterile technique protocol Pre-treatment screening "Professional medical standards applied to every treatment since 2016." Ready to Experience Myers Cocktail IV Therapy
Detox support Who it may fit Adults seeking antioxidant support for daily wellness or those with high-stress, busy lifestyles
"Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice." Biogerontology
A significant reduction in the fear of self-injection from baseline to the end of the study was also reported [238]
[7] [8] For long-term home-PN, retrospective analyses suggest that a median dose of 7.6 mg/day maintained normozincemia in 90 % of adults, but individualized adjustments based on stool or fistula output were still required